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Abstract 
Purpose: Centralization of surgery improves the survival following esophagectomy for 
cancer, but whether university hospital setting or surgeon volume influences the reoperation 
rates is unknown. We aimed to clarify whether hospital status or surgeon volume are 
associated with a risk of reoperation after esophagectomy. 
Methods: Patients who underwent esophagectomy for esophageal cancer in 1987-2010 were 
identified from a population-based, nationwide Swedish cohort study. University hospital 
status and cumulative surgeon volume were analyzed in relation to risk of reoperation or 
death (the latter included to avoid competing risk errors) within 30 days of surgery. 
Multivariable logistic regression provided odds ratios (OR) with 95% confidence intervals 
(CI), adjusted for calendar period, age, sex, comorbidity, tumor histology, stage, neoadjuvant 
therapy, resection margin, surgeon volume, and hospital status. 
Results: Among 1820 participants, 989 (54%) underwent esophagectomy in university 
hospitals and 271 (15%) died or were reoperated within 30 days of surgery. Non-university 
hospital status was associated with an increased risk of reoperation or death compared to 
university hospitals (adjusted OR 1.56, 95% CI 1.13-2.13). Regarding surgeon volume, the 
ORs were increased in the lower volume categories, but not statistically significant (OR 1.30, 
95% CI 0.89-1.89 for surgeon volume <7 and OR 1.10, 95% CI 0.75-1.63 for surgeon volume 
7-16, compared to surgeon volume >16).  
Conclusion: The risk of reoperation or death within 30 days of esophagectomy seems to be 
lower in university hospitals even after adjustment for surgeon volume and other potential 
confounders. These results support centralizing esophageal cancer patients to university 
hospitals. 
Keywords: neoplasm; esophagus, esophagectomy; surgery  
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1. Introduction 
The curative treatment of esophageal cancer includes surgical resection (esophagectomy) in 
most patients.[1] One of several potential reasons for the improved 5-year survival of 
esophageal cancer patients in the last decade is centralization of surgery.[1, 2] Surgeon 
volume is a known long-term prognostic factor in esophageal cancer surgery,[3] and higher 
annual esophagectomy volume may lower early postoperative mortality after esophagectomy 
regardless of comorbidity.[4, 5] However, hospital volume is not prognostic after adjustment 
for individual surgeon volume.[3, 6]  
University hospital status has not been shown to be associated with long-term survival of 
esophageal cancer patients.[7] However, university hospitals should be more experienced in 
the perioperative treatment of patients undergoing major thoraco-abdominal surgery due to a 
higher case load of other procedures, for example cardiac and lung cancer surgery, and have 
greater staffing and more research activities. Instead of prolonged survival, university hospital 
status might be associated with lower complication or reoperation rates, which in turn may 
cause poor quality of life also in the long-term perspective.[8] The collection of data 
concerning complications, as well as reporting of complications, has varied greatly in 
individual studies.[9] Therefore, reoperation and short-term mortality could be considered a 
more robust and specific assessment of poor early postoperative outcomes than complications 
in historical cohorts. Reoperations are also known to decrease the long-term survival after 
esophagectomy.[10] Yet, the relation between university hospital status, or surgeon volume 
and risk of reoperations is not known.  
The aim of this study was to test the hypotheses that esophagectomy for esophageal cancer in 
university hospitals and conducted by high-volume surgeons is associated with lower rates of 
reoperation than in non-university hospitals and lower volume surgeons.   
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2. Methods 
2.1. Study design 
This was a population-based and nationwide cohort study of patients diagnosed with 
adenocarcinoma or squamous cell carcinoma of the esophagus who had undergone 
esophagectomy in Sweden between 1987 and 2010, with follow-up until 2016.  
2.2. Exposures 
The study main exposure was university versus non-university hospital status where the 
esophagectomy was conducted. University hospital was defined as any of the six hospitals 
affiliated to a university providing education and training for medical students in Sweden, and 
the remaining 49 hospitals that had conducted esophagectomies during the study period were 
considered non-university hospitals. The secondary exposure was the cumulative surgeon 
volume of the individual surgeon during the study period, where <7 was the lowest quartile, 
7-16 was the second quartile, and >16 esophagectomies defined the two highest quartiles. 
Surgeon volume was chosen instead of hospital volume because surgeon volume is more 
robust predictor of surgeon skill compared to hospital volume, and because hospital volume is 
not prognostic after adjustment for individual surgeon volume.[3] The algorithm to determine 
the surgeon volume has been described earlier.[3] Highest two volume quartile surgeons were 
grouped into one category because there were much more high-volume surgeons operating in 
university hospitals, and because esophagectomy-associated short-term mortality has been 
shown to plateau after cumulative surgeon volume of 15.[11] 
2.3. Outcomes 
The primary outcome was the occurrence of reoperation or death within 30 days of primary 
surgery. The secondary outcome was reoperation alone within 30 days of primary surgery. 
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The primary outcome was chosen to include 30-day all-cause mortality to reduce competing 
risk errors from mortality before any reoperation was possible. The study was approved by the 
Regional Ethical Review Board in Stockholm, Sweden. 
 
2.4. Cohort 
Earlier versions of the cohort of this study have been used for other studies examining 
esophageal cancer surgery.[3, 11-13] In brief, the study cohort included at least 98% of all 
esophageal cancer patients who underwent curatively intended surgery in Sweden during the 
study period. The patients with esophageal cancer were identified from the Swedish Cancer 
Registry, which we have shown to have at least 98% completeness for this cancer.[14] 
Additionally, the Swedish Patient Registry was used for selecting only patients who had 
undergone esophagectomy, and this registry has 99.6% positive predictive value for this 
operation.[15] The Patient Registry also provided information about patient characteristics 
(age, sex, and comorbidity) and hospital status (university or non-university). Comorbidity 
data were defined and categorized using the most updated and well-validated Charlson 
Comorbidity Index.[16]  
To enable collection of additional and more detailed clinical data, surgery charts and 
pathology records were retrieved from all hospitals conducting esophageal cancer surgery in 
Sweden during the study period. The data retrieved from the medical records were assessed 
and categorized according to a detailed predefined protocol to ensure uniformity. This 
assessment has been validated for high concordance.[12] The medical records provided 
information about reoperations, surgeon volume, tumor characteristics (location, stage and 
histology), as well as details regarding the treatment (type of surgery, radicalness of the 
resection and neoadjuvant therapy). Tumor stage was classified based on the Union 
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Internationale Contre le Cancer, using the 7th edition of tumor-node-metastasis (TNM) 
system.[17] Open transthoracic resection with intrathoracic anastomosis was the dominant 
(>95%) surgical procedure and a gastric tube which was pulled up and anastomosed to the 
proximal esophagus was the preferred reconstruction.   
Mortality data were obtained from the nationwide Swedish Causes of death Registry, which 
has 100% complete data for date of death.  
The information from the registries and medical records was linked for all individual patients 
using the Swedish personal identity number, a unique 10-digit identifier assigned to each 
Swedish resident upon birth or immigration, which is a well-validated tool for research 
purposes.[18] 
 
2. 5. Statistical analysis 
All statistical analyses were carried out by an experienced biostatistician (KW), who followed 
an a priori specified study protocol, defining and categorizing the exposures, outcomes and 
covariates as well as the statistical methods. To estimate the relative risk for the exposures in 
relation to the outcomes, multivariable logistic regression was used to calculate odds ratios 
(OR) with 95% confidence intervals (CI). The following covariates were selected and 
adjusted for as potential confounders: 1) calendar period of surgery (year 1987-1994, 1995-
2002, or 2003-2010), 2) age (categorized into <65, 65-75, or >75 years), 3) sex (male or 
female), 4) comorbidity (Charlson Comorbidity Index score 0, 1, or ≥2), 5) tumor histology 
(adenocarcinoma or squamous cell carcinoma), 6) tumor stage (0-I, II or III-IV), 7) 
neoadjuvant therapy (yes or no), 8) resection margin status (radical [R0] or not [R1/2]), 9) 
surgeon volume (<7, 7-16, or >16, the cumulative number of esophagectomies per surgeon 
during the study period), and 10) hospital status (university or non-university). Three 
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regression models were created, i.e. a crude model without any adjustments, a Model 1 with 
adjustment for covariates 1-8 above, and Model 2 which additionally adjusted for surgeon 
volume for the exposure hospital status and hospital status for the exposure surgeon volume. 
Subgroup analyses were also conducted stratifying by the covariates 1-8 above, with 
adjustment for the other covariates. Missing data were handled by carrying out a complete 
case analysis. The statistical software IBM SPSS v24.0 (IBM Corp., Armonk, NY) was used 
for all statistical analyses. 
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3. Results 
3.1. Patients 
Among 1820 participating patients, 989 (54%) underwent esophagectomy in a university 
hospital and 876 (50%) by surgeons with cumulative volume >16 esophagectomies. The 
distribution of patient characteristics was similar between those who underwent surgery in 
university hospitals and in non-university hospitals, except that the proportion of more 
advanced stage tumors and the proportion of patients operated by surgeons in the highest 
volume group were higher in university hospitals (Table 1). High-volume surgeons operated 
proportionally more patients in the most recent time period, and high volume surgeons had 
higher lymph node yield, compared to low-volume surgeons (Table 2). Reoperation or death 
within 30 days of surgery occurred in 271 (15%) patients, and reoperations only were found 
in 200 (11%) patients. 
 
3.2. University hospital status and risk of reoperation 
The composite outcome reoperation or death within 30 days of surgery was 64% more likely 
to occur in non-university hospitals, compared to university hospitals (OR 1.64, 95% CI 1.22 
– 2.19 in adjusted Model 1) (Table 3). After additional adjustment for surgeon volume (Model 
2), the risk was 56% increased (OR 1.56, 95% CI 1.13 – 2.13).  
The risk of reoperation alone was also more likely in non-university hospitals than in 
university hospitals (OR 1.43, 95% CI 1.03 – 1.98 in adjusted Model 1), and this association 
was stable (41% increased) after additional adjustment for surgeon volume (adjusted OR 1.41, 
95% 0.99 – 2.01 in adjusted Model 2) (Table 3). 
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Compared to university hospitals, esophagectomy conducted at non-university hospitals was 
associated with increased point estimates for reoperation or death in all stratified analyses, 
and were statistically significantly increased in patients operated in 1995-2002, aged <65 
years, of female sex, with esophageal squamous cell carcinoma, not receiving neoadjuvant 
therapy, and in patients with radical (R0) resection (Table 4).  
Esophagectomy conducted at non-university hospitals was associated with increased point 
estimates for reoperation only in almost all stratified analyses, and in patients aged <65 years 
and those with esophageal squamous cell carcinoma the ORs were also statistically 
significantly increased (Table 4). 
 
3.3. Surgeon volume and risk of reoperation 
The risk of the composite outcome of reoperation or death within 30 days of surgery was 
higher in the lowest cumulative surgeon volume group compared to highest in the adjusted 
Model 1 (OR 1.53, 95% CI 1.07 – 2.18 for <7 vs >16 esophagectomies and OR 1.24, 95% CI 
0.85 – 1.81 for 7-16 vs >16 esophagectomies) (Table 5). After additional adjustment for 
university hospital status, the associations were attenuated and no longer statistically 
significant (OR 1.30, 95% CI 0.89 – 1.89 for <7 vs >16 esophagectomies and OR 1.10, 95% 
CI 0.75 – 1.63 for 7-16 vs >16 esophagectomies).  
Although almost all ORs were above 1, no statistically significant associations were found 
between surgeon volume and risk of reoperation alone in any of the models (Table 5). 
In the stratified analyses, surgeon volume <7 versus >16 was statistically significantly 
associated with increased HRs of reoperation or death within 30 days of surgery in patients 
aged 65-75 years and in patients receiving neoadjuvant therapy (Table 6). Cumulative surgeon 
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volume of 7-16 versus >16 was also associated with higher risk of reoperation or death in 30 
days in patients with Charlson’s comorbidity score 1 (Table 6).  
No statistically significant associations between surgeon volume and reoperations alone were 
found in the stratified analysis (Table 6).   
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4. Discussion 
The present study suggests that surgery for esophageal cancer conducted at university 
hospitals is associated with decreased risk of reoperation within 30 days of surgery 
independent of other variables, including surgeon volume, compared to non-university 
hospitals. Higher surgeon volume also seemed to decrease the risk of reoperation, but this 
influence did not remain after adjustment for university hospital status. 
One of the main strengths of the study is the population-based design with virtually complete 
inclusion of all patients undergoing surgery for esophageal cancer in the entire Sweden. 
Accurate information about the exposures, outcomes and relevant covariates was made 
possible by virtue of a combination of data retrieval from validated and nationwide registries 
and ambitious collection of medical records. The use of a predefined data retrieval form and 
specific study protocol reduced the risk of chance findings and systematic errors. The reliable 
identification of all eligible patients and the complete follow-up was made possible by the 
uniquely assigned personal identity numbers and high-quality cancer and patient registries. A 
limitation of observational studies is confounding. However, this was counteracted by 
adjusting for several potential confounders, though residual confounding cannot be ruled out. 
The lower number of high volume surgeons operating in the non-university hospitals 
compared to university hospitals might be considered a limitation. However, a previous study 
using the same cohort as in the present study showed that short-term mortality does plateau 
after 15 cumulative esophagectomies which should alleviate these concerns.[11] Competing 
risk by mortality is a source of error when studying reoperations, because some patients who 
might have undergone reoperation may have died before the reoperation could be conducted. 
Therefore, reoperation and death within 30 days were assessed as a combined outcome and 
compared with the reoperation alone outcome. The lack of the indications for the reoperations 
was a limitation of the study, but the assessment of reoperation or death was highly complete 
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and accurate. Finally, chance might influence the results, particularly in the stratified 
analyses. However, the large sample size provided robust estimates of the main analyses.  
 
Complications are common following resectional surgery for esophageal cancer. When 
complications occur and the patient deteriorates, the surgeon might need to choose between 
reoperation, non-surgical intervention, or “watchful waiting”, depending on several factors. 
Increasing surgeon volume might decrease the risk of reoperations,[11] which might be 
related to more experienced surgeons encountering fewer complications and being more 
inclined to watch and wait when complications occur with support from experienced 
colleagues. Surgeons with more experience in esophagectomy often work in university 
hospitals, at least in Sweden. Yet, the results of the present study show that the hospital status 
per se influences the incidence of reoperation, i.e. also after adjustment for potential 
confounders, including surgeon volume. A contributing factor might be that university 
hospitals have more experience in the intensive care of thoracic and major cancer surgery 
patients. Psychological factors relating to the surgeons might also affect the decision whether 
to reoperate or not. Non-university hospitals in Sweden are smaller and have fewer surgeons 
with experience in a very specialized field, such as esophageal cancer surgery, compared to 
university hospitals. The lack of feedback from experienced colleagues in non-university 
hospitals might make the operating surgeon more likely to reoperate, compared to in 
university hospitals where decisions are more likely made in teams and discussed with other 
surgeons with experience of these operations. These results may be difficult to generalize to 
countries with different types of healthcare policies, and therefore it would be important to 
study the risk of reoperation in relation to hospital status in other countries and settings as 
well. 
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Reoperations are associated with worse long-term prognosis,[10] and also clearly worse long-
term deterioration in health-related quality of life,[8] and the results of the present study 
indicate the need for continued centralization of esophageal cancer surgery into high-volume 
centers within university hospitals. After the end of the inclusion of the current study, 
esophagectomies have been centralized to university hospitals in Sweden. However, the 
complex procedure of esophagectomy is still being conducted in many smaller hospitals in 
Europe. The patients with such malignant disease should be offered the best available care, 
and the centralization of esophagectomies from smaller units to university hospitals should be 
carefully considered in the context of each country and area. 
 
In conclusion, this nationwide Swedish study found that risk of reoperation within 30 days of 
resectional surgery for esophageal cancer is likely favorably influenced by university hospital 
status, because the association remains after adjustment for surgeon volume and several other 
potential confounders. Continued and intensified measures to centralize these operations to 
university hospitals are encouraged.  
5. Acknowledgements 
This study was supported by grants from the Swedish Cancer Society (JL), Swedish Research 
Council (JL), Sigrid Jusélius Foundation (JHK) and Orion Research Foundation (JHK). 
 
6. Role of the funding source 
The study sponsors had no role in the design of the study, data collection, analysis or 
interpretation of the results, the writing of the manuscript or the decision to submit the 
manuscript for publication.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
14 
 
7. Conflict of Interest Statement 
The authors declare no potential conflicts of interest. 
   
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
15 
 
References 
 
Refere nce s  
 
1. Lagergren J and Lagergren P. Recent developments in esophageal 
adenocarcinoma. CA Cancer J Clin 2013;63:232-48.  
2. van Hagen P, et al. Preoperative chemoradiotherapy for esophageal or 
junctional cancer. N Engl J Med 2012;366:2074-84.  
3. Derogar M, et al. Hospital and surgeon volume in relation to survival after 
esophageal cancer surgery in a population-based study. J Clin Oncol 2013;31:551-7.  
4. Pasquer A, et al. Is Centralization Needed for Esophageal and Gastric Cancer 
Patients With Low Operative Risk?: A Nationwide Study. Ann Surg 2016;264:823-30.  
5. Ra J, et al. Postoperative mortality after esophagectomy for cancer: 
Development of a preoperative risk prediction model. Annals of Surgical Oncology 
2008;15:1577-84.  
6. Brusselaers N, et al. Hospital and surgeon volume in relation to long-term 
survival after oesophagectomy: systematic review and meta-analysis. Gut 2014;63:1393-400.  
7. Markar SR, et al. University hospital status and prognosis following surgery for 
esophageal cancer. Eur J Surg Oncol 2016;42:1191-5.  
8. Derogar M, et al. Influence of major postoperative complications on health-
related quality of life among long-term survivors of esophageal cancer surgery. J Clin Oncol 
2012;30:1615-9.  
9. Low DE, et al. International Consensus on Standardization of Data Collection for 
Complications Associated With Esophagectomy: Esophagectomy Complications Consensus 
Group (ECCG). Ann Surg 2015;262:286-94.  
10. van der Schaaf M, et al. Reoperation after oesophageal cancer surgery in 
relation to long-term survival: a population-based cohort study. BMJ Open 2014;4:e004648.  
11. Markar SR, et al. Surgical Proficiency Gain and Survival After Esophagectomy 
for Cancer. J Clin Oncol 2016;34:1528-36.  
12. Rouvelas I, et al. Survival after surgery for oesophageal cancer: a population-
based study. Lancet Oncol 2005;6:864-70.  
13. van der Schaaf M, et al. Extent of lymph node removal during esophageal 
cancer surgery and survival. J Natl Cancer Inst 2015;107.  
14. Lagergren K and Derogar M. Validation of oesophageal cancer surgery data in 
the Swedish Patient Registry. Acta Oncol 2012;51:65-8.  
15. Lindblad M, et al. Disparities in the classification of esophageal and cardia 
adenocarcinomas and their influence on reported incidence rates. Ann Surg 2006;243:479-
85.  
16. Armitage JN, et al. Identifying co-morbidity in surgical patients using 
administrative data with the Royal College of Surgeons Charlson Score. Br J Surg 
2010;97:772-81.  
17. Sobin LH, et al. TNM classification of malignant tumours. 7th ed. Chichester, 
West Sussex, UK ; Hoboken, NJ: Wiley-Blackwell; 2010. 
18. Ludvigsson JF, et al. The Swedish personal identity number: possibilities and 
pitfalls in healthcare and medical research. Eur J Epidemiol 2009;24:659-67.  
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
16 
 
Table 1. Characteristics of the 1820 patients who underwent resectional surgery for 
esophageal cancer in 1987-2010 in Sweden stratified by hospital status.   
 University 
hospital 
Non-university 
hospital 
Total 
 Patients 
Number (%) 
Patients 
Number (%) 
Patients 
Number (%) 
Total 989 (100) 831 (100) 1820 (100) 
 
   
Time period    
1987-1994 365 (37) 248 (30) 613 (34) 
1995-2002 275 (28) 358 (43) 633 (35) 
2003-2010 349 (35) 225 (27) 574 (32) 
 
   
Age (in years)    
<65 468 (47) 384 (46) 850 (47) 
65-75 368 (37) 326 (39) 694 (38) 
>75 155 (16) 121 (15) 276 (15) 
 
   
Sex     
Male 733 (75) 627 (74) 1360 (75) 
Female 256 (25) 204 (26) 460 (25) 
    
Charlson’s comorbidity score    
0 596 (60) 505 (61) 1101 (61) 
1 240 (24) 205 (25) 445 (25) 
≥2 153 (16) 121 (15) 274 (15) 
    
Tumor histology    
Adenocarcinoma 403 (41) 389 (47) 792 (44) 
Squamous cell carcinoma 583 (59) 441 (53) 1024 (56) 
Missing 3 (0) 1 (0) 4 (0) 
    
Tumor stage    
0-I 210 (21) 212 (26) 422 (23) 
II 353 (36) 309 (37) 662 (36) 
III-IV 420 (42) 302 (36) 722 (40) 
Missing 6 (1) 8 (1) 14 (1) 
    
Neoadjuvant therapy    
No 678 (69) 553 (67) 1231 (68) 
Yes 309 (31) 278 (34) 587 (32) 
Missing 2 (0) 0 (0) 2 (0) 
    
Lymph node yield (median 
[interquartile range]) 
8 [5 – 18] 7 [4 – 12] 7 [4 – 15] 
Missing 231 (23) 242 (29) 473 (26) 
    
Resection margin status    
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Radical (R0) 705 (71) 567 (68) 1272 (70) 
Non-radical (R1/R2) 155 (16) 126 (15) 281 (15) 
Missing 129 (13) 138 (17) 267 (15) 
    
Cumulative surgeon volume    
Low (<7) 176 (18) 313 (38) 489 (27) 
Medium (7-16) 179 (18) 216 (26) 395 (22) 
High (>16) 608 (61) 268 (32) 876 (48) 
Missing 26 (3) 34 (4) 60 (2) 
    
Length of hospital stay (median 
[interquartile range]) 
15 [13 – 22] 16 [12 – 23] 15 [12 – 22] 
    
Reoperation    
No 897 (91) 723 (87) 1620 (89) 
Yes 92 (9) 108 (13) 200 (11) 
    
Reoperation or death     
No 869 (88) 680 (82) 1549 (85) 
Yes 120 (12) 151 (18) 271 (15) 
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Table 2. Characteristics of patients who underwent resectional surgery for esophageal cancer 
in 1987-2010 in Sweden stratified by surgeon volume (n=1760). 
 Low 
surgeon 
volume 
(<7) 
Medium 
surgeon 
volume 
(7 – 16) 
High 
surgeon 
volume 
(>16) 
Total 
 Patients 
Number 
(%) 
Patients 
Number 
(%) 
Patients 
Number (%) 
Patients 
Number (%) 
Total 489 (100) 395 (100) 876 (100) 1760 (100) 
 
    
Time period     
1987-1994 253 (52) 132 (33) 190 (22) 575 (33) 
1995-2002 140 (29) 141 (36) 333 (38) 614 (35) 
2003-2010 96 (20) 122 (31) 353 (40) 571 (32) 
 
    
Age (in years)     
<65 221 (45) 183 (46) 426 (49) 830 (47) 
65-75 192 (39) 158 (40) 319 (36) 669 (38) 
>75 76 (16) 54 (14) 131 (15) 261 (15) 
 
    
Sex      
Male 368 (75) 305 (77) 642 (73) 1315 (75) 
Female 121 (25) 90 (23) 234 (27) 445 (25) 
     
Charlson’s comorbidity score     
0 330 (68) 245 (62) 493 (56) 1068 (61) 
1 99 (20) 102 (26) 224 (26) 425 (24) 
≥2 60 (12) 48 (12) 160 (18) 267 (15) 
     
Tumor histology     
Adenocarcinoma 204 (42) 173 (44) 395 (45) 772 (44) 
Squamous cell carcinoma 285 (58) 221 (56) 479 (55) 985 (56) 
Missing 0 (0) 1 (0) 2 (0) 3 (0) 
 
    
Tumor stage     
0-I 102 (21) 97 (25) 212 (24) 311 (23) 
II 166 (34) 155 (39) 318 (36) 639 (36) 
III-IV 219 (45) 141 (36) 342 (39) 702 (40) 
Missing 2 (0) 2 (1) 4 (0) 8 (0) 
     
Neoadjuvant therapy     
No 336 (69) 245 (62) 613 (70) 1194 (68) 
Yes 153 (31) 150 (38) 263 (30) 566 (32) 
     
Lymph node yield (median 
[interquartile range]) 
5 [3 – 11] 7 [4 - 13] 10 [5 – 18] 7 [4 – 15] 
Missing 152 (31) 106 (27) 195 (22) 453 (26) 
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Resection margin status     
Radical (R0) 309 (63) 270 (68) 652 (74) 1231 (70) 
Non-radical (R1/R2) 91 (19) 62 (16) 118 (13) 271 (15) 
Missing 89 (18) 63 (16) 106 (12) 258 (15) 
 
    
Length of hospital stay 
(median [interquartile range]) 
16 [13 – 23] 15 [12 – 22] 15 [12 – 22] 15 [12 – 22] 
 
    
Reoperation     
No 433 (89) 344 (87) 789 (90) 1566 (89) 
Yes 56 (11) 51 (13) 87 (10) 194 (11) 
     
Reoperation or death      
No 398 (81) 329 (83) 772 (88) 1499 (85) 
Yes 91 (19) 66 (17) 104 (12) 261 (15) 
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Table 3. Hospital status and risk of reoperation or death within 30 days of resectional surgery 
in patients with esophageal cancer, expressed as odds ratios (OR) with 95% confidence 
intervals (CI). Missing values were handled by conducting a complete case analysis. 
 
Model Number of 
patients 
Reoperation or death Reoperation 
University 
hospital 
Non-university 
hospital 
University 
hospital 
Non-university 
hospital 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Crude 1820 1 (reference) 1.61 (1.24 – 2.09) 1 (reference) 1.46 (1.09 – 1.96) 
Model 1* 1552 1 (reference) 1.64 (1.22 – 2.19) 1 (reference) 1.43 (1.03 – 1.98) 
Model 2** 1501 1 (reference) 1.56 (1.13 – 2.13) 1 (reference) 1.41 (0.99 – 2.01) 
*Adjusted for time period, age, sex, Charlson’s Comorbidity Index, histology, tumor stage, 
neoadjuvant therapy and resection margin status. 
** Adjusted for the confounders in Model 1, and additionally for surgeon volume. 
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Table 4. Stratified analysis on hospital status and risk of reoperation or death within 30 days 
of resectional surgery in patients with esophageal cancer, expressed as odds ratios (OR) with 
95% confidence intervals (CI) in each subgroup.  
 Reoperation or death Reoperation 
 University 
hospital 
Non-university 
hospital 
University 
hospital 
Non-university 
hospital 
 OR (95% CI) OR (95% CI)* OR (95% CI) OR (95% CI)* 
Time period     
1987-1994 1 (reference) 1.60 (0.93 – 2.75) 1 (reference) 1.22 (0.65 – 2.31) 
1995-2002 1 (reference) 1.77 (1.00 – 3.11) 1 (reference) 1.53 (0.81 – 2.86) 
2003-2010 1 (reference) 1.33 (0.74 – 2.40) 1 (reference) 1.50 (0.80 – 2.79) 
 
    
Age (in years)     
<65 1 (reference) 1.91 (1.16 – 3.13) 1 (reference) 1.71 (1.02 – 2.88) 
65-75 1 (reference) 1.23 (0.75 – 2.03) 1 (reference) 1.24 (0.70 – 2.19) 
>75 1 (reference) 1.78 (0.75 – 4.25) 1 (reference) 0.82 (0.26 – 2.62) 
 
    
Sex     
Male 1 (reference) 1.38 (0.96 – 2.00) 1 (reference) 1.28 (0.84 – 1.93) 
Female 1 (reference) 2.03 (1.08 – 3.80) 1 (reference) 1.64 (0.82 – 3.27) 
     
Charlson’s comorbidity score     
0 1 (reference) 1.75 (1.15 – 2.68) 1 (reference) 1.54 (0.97 – 2.45) 
1 1 (reference) 1.60 (0.83 – 3.09) 1 (reference) 1.18 (0.58 – 2.39) 
≥2 1 (reference) 1.20 (0.56 – 2.58) 1 (reference) 1.59 (0.61 – 4.07) 
     
Tumor histology     
Adenocarcinoma 1 (reference) 1.22 (0.70 – 2.12) 1 (reference) 1.06 (0.58 – 1.93) 
Squamous cell carcinoma 1 (reference) 1.77 (1.20 – 2.62) 1 (reference) 1.58 (1.01 – 2.46) 
     
Tumor stage     
0-I 1 (reference) 1.58 (0.81 – 3.06) 1 (reference) 1.42 (0.70 – 2.89) 
II 1 (reference) 1.56 (0.96 – 2.56) 1 (reference) 1.40 (0.81 – 2.42) 
III-IV 1 (reference) 1.51 (0.87 – 2.61) 1 (reference) 1.39 (0.74 – 2.60) 
     
Neoadjuvant therapy     
No 1 (reference) 1.77 (1.18 – 2.67) 1 (reference) 1.55 (0.97 – 2.47) 
Yes 1 (reference) 1.38 (0.83 – 2.30) 1 (reference) 1.32 (0.76 – 2.29) 
     
Resection margin status     
Radical (R0) 1 (reference) 1.46 (1.03 – 2.08) 1 (reference) 1.38 (0.94 – 2.04) 
Non-radical (R1/R2) 1 (reference) 1.95 (0.91 – 4.17) 1 (reference) 1.37 (0.54 – 3.44) 
* Adjusted for calendar period, age, sex, comorbidity, histology, tumor stage, neoadjuvant 
therapy, resection margin status and surgeon volume, except for the covariate that the analysis 
was stratified by.  
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Table 5. Cumulative surgeon volume and risk of reoperation or death within 30 days of resectional surgery in patients with esophageal cancer, 
expressed as odds ratios (OR) with 95% confidence intervals (CI). Missing values were handled by conducting a complete case analysis. 
 
Model Number of 
patients 
Reoperation or death Reoperation 
  Surgeon 
volume >16 
Surgeon volume 7-
16 
Surgeon volume <7 Surgeon 
volume >16 
Surgeon volume 7-
16 
Surgeon volume <7 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Crude 1760 1 (reference) 1.49 (1.07 – 2.08) 1.70 (1.25 – 2.31) 1 (reference) 1.35 (0.93 – 1.94) 1.17 (0.82 – 1.67) 
Model 1* 1501 1 (reference) 1.24 (0.85 – 1.81) 1.53 (1.07 – 2.18) 1 (reference) 1.19 (0.79 – 1.80) 1.09 (0.72 – 1.64) 
Model 2** 1501 1 (reference) 1.10 (0.75 – 1.63) 1.30 (0.89 – 1.89) 1 (reference) 1.09 (0.72 – 1.67) 0.96 (0.62 – 1.48) 
*Adjusted for time period, age, sex, Charlson’s Comorbidity Index, histology, tumor stage, neoadjuvant therapy and resection margin status. 
** Adjusted for the confounders in Model 1, and additionally for university hospital status.  
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Table 6. Stratified analysis on cumulative surgeon volume and risk of reoperation or death within 30 days of resectional surgery in patients with 
esophageal cancer, expressed as odds ratios (OR) with 95% confidence intervals (CI) in each subgroup. 
 
Model Reoperation or death Reoperation 
 Surgeon 
volume >16 
Surgeon volume 
7-16 
Surgeon volume <7 Surgeon 
volume >16 
Surgeon volume 7-16 Surgeon volume <7 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Time period       
1987-1994 1 (reference) 0.92 (0.43 – 1.97) 1.69 (0.88 – 3.16) 1 (reference) 0.76 (0.32 – 1.81) 1.20 (0.58 – 2.45) 
1995-2002 1 (reference) 1.61 (0.85 – 3.03) 1.43 (0.73 – 2.80) 1 (reference) 1.75 (0.88 – 3.49) 1.06 (0.47 – 2.37) 
2003-2010 1 (reference) 0.85 (0.42 – 1.74) 0.72 (0.32 – 1.62) 1 (reference) 0.85 (0.40 – 1.79) 0.62 (0.25 – 1.51) 
 
      
Age (in years)       
<65 1 (reference) 1.01 (0.55 – 1.85) 1.06 (0.59 – 1.90) 1 (reference) 1.22 (0.66 – 2.27) 1.01 (0.54 – 1.91) 
65-75 1 (reference) 1.38 (0.74 – 2.57) 1.93 (1.08 – 3.47) 1 (reference) 1.16 (0.58 – 2.32) 1.16 (0.59 – 2.28) 
>75 1 (reference) 1.03 (0.36 – 2.91) 0.95 (0.34 – 2.66) 1 (reference) 1.06 (0.29 – 3.95) 0.55 (0.13 – 2.38) 
 
      
Sex        
Male 1 (reference) 1.06 (0.67 – 1.67) 1.26 (0.81 – 1.94) 1 (reference) 1.00 (0.61 – 1.65) 0.95 (0.57 – 1.56) 
Female 1 (reference) 1.33 (0.61 – 2.86) 1.57 (0.73 – 3.39) 1 (reference) 1.45 (0.64 – 3.29) 1.07 (0.44 – 2.57) 
       
Charlson’s 
comorbidity score 
      
0 1 (reference) 0.76 (0.43 – 1.33) 1.14 (0.70 – 1.85) 1 (reference) 0.84 (0.47 – 1.51) 0.88 (0.51 – 1.52) 
1 1 (reference) 2.13 (1.03 – 4.43) 1.17 (0.49 – 2.76) 1 (reference) 2.10 (0.95 – 4.63) 1.13 (0.44 – 2.92) 
≥2 1 (reference) 1.01 (0.38 – 2.68) 1.74 (0.71 – 4.25) 1 (reference) 0.89 (0.27 – 2.90) 0.85 (0.26 – 2.75) 
       
Tumor histology       
Adenocarcinoma 1 (reference) 1.06 (0.53 – 2.12) 1.58 (0.53 – 2.12) 1 (reference) 1.20 (0.57 – 2.50) 1.40 (0.69 – 2.86) 
Squamous cell 
carcinoma 
1 (reference) 1.10 (0.69 – 1.78) 1.19 (0.74 – 1.91) 1 (reference) 1.01 (0.60 – 1.72) 0.79 (0.45 – 1.39) 
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Tumor stage       
0-I 1 (reference) 0.76 (0.33 – 1.79) 1.40 (0.65 – 3.02) 1 (reference) 0.94 (0.40 – 2.23) 0.94 (0.38 – 2.28) 
II 1 (reference) 1.44 (0.81 – 2.57) 1.59 (0.88 – 2.87) 1 (reference) 1.16 (0.61 – 2.21) 1.17 (0.60 – 2.27) 
III-IV 1 (reference) 0.92 (0.44 – 1.90) 1.08 (0.57 – 2.07) 1 (reference) 1.20 (0.55 – 2.59) 0.91 (0.43 – 1.93) 
       
Neoadjuvant therapy       
No 1 (reference) 0.96 (0.58 – 1.59) 0.93 (0.67 – 1.52) 1 (reference) 1.11 (0.64 – 1.90) 0.63 (0.35 – 1.15) 
Yes 1 (reference) 1.26 (0.66 – 2.37) 2.07 (1.13 – 3.81) 1 (reference) 1.00 (0.50 – 2.01) 1.64 (0.85 – 3.15) 
       
Resection margin 
status 
      
Radical (R0) 1 (reference) 0.94 (0.60 – 1.46) 1.20 (0.79 – 1.82) 1 (reference) 0.94 (0.59 – 1.51) 0.90 (0.56 – 1.45) 
Non-radical (R1/R2) 1 (reference) 2.09 (0.82 – 5.32) 2.05 (0.82 – 5.15) 1 (reference) 2.15 (0.72 – 6.38) 1.41 (0.47 – 4.25) 
* Adjusted for calendar period, age, sex, comorbidity, histology, tumor stage, neoadjuvant therapy, resection margin status and surgeon volume, 
except for the covariate that the analysis was stratified by. 
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